Navigation Links
Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
Date:6/20/2013

PISCATAWAY, N.J., June 20, 2013 /PRNewswire/ -- On June 13, 2013, the United States Supreme Court unanimously ruled that although isolated, natural gene sequences are unpatentable, cDNA (referred to as synthetic DNA) is officially considered patentable subject material. The ruling was issued after the court reviewed patents owned by Myriad Genetics Inc. in the high-profile case Association for Molecular Pathology v. Myriad Genetics. The patents claimed the genes BRCA1 and BRCA2, as well as methods for detecting mutations in the genes that have been linked to breast and ovarian cancer. The court supported this legal claim, stating that "cDNA is not a 'product of nature,' so it is patent eligible …".

GenScript's gene synthesis service is a valuable method for circumventing the isolation of natural DNA sequences for use in biological research studies. The service provides non-natural, de novo DNA sequences synthesized according to specified client design, allowing natural gene sequences or cassettes to be engineered for in vivo, or in vitro use, including diagnostic tests. Additionally, GenScript's OptimumGene(TM) codon optimization technology can alter the sequence of natural genes, to increase the expression of the subsequent protein in a number of systems. The OptimumGeneTM algorithm considers nearly every parameter affecting the central dogma process, from transcription to protein folding, and has been proven to optimize protein production in bacterial, mammalian, yeast and insect expression systems. OptimumGeneTM codon optimization in combination of gene synthesis can generate novel, non-naturally occurring sequences, with high-utility and attractive patentable features. To preserve clients' intellectual property rights, GenScript does not claim any rights to specialized synthetic or OptimumGeneTM codon optimized genes. Custom project details are kept strictly confidential; all intellectual property rights belong to the client.

It may be too soon to speculate on the court ruling's effect on DNA sequences' future patentability. However, as the pace of molecular biology research quickens, the use of synthetic DNA will inevitably become a mainstay in every lab. GenScript offers gene synthesis and codon optimization solutions for the present and future of gene patent law and remains committed to supporting innovation.

*GenScript is not a legal practitioner and the content above is in no way intended to provide legal advice for patent prosecution, litigation or any associated legal matters thereof.


'/>"/>
SOURCE GenScript USA Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
2. Synthetic Biology: Emerging Global Markets
3. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
4. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
5. Startling results in synthetic chemistry presented in Nature Chemistry
6. Adeona Becomes Synthetic Biologics, Inc.
7. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
8. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
9. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
10. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
11. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... March 22, 2017...Council for Agricultural Science and Technology, ... that utilizes technological innovation in smart, sustainable ways. Humans depend on plants for food, ... and environmental stability. This paper is the first in a series that connects science ...
(Date:3/22/2017)... , March 22, 2017  Personal Genome ... its cancer testing contract with the U.S. Department ... tumor profiling assay with the company,s new CancerSELECT ... comprehensive, clinically actionable pan-cancer profiling test that includes ... assess potential patient response to checkpoint inhibitor immunotherapies. ...
(Date:3/22/2017)... March 22, 2017   Invitae Corporation ... information companies, today announced the availability of a ... Spinal Muscular Atrophy (SMA) , a neuromuscular disease ... disorders among infants as well as a significant ... new test, announced during the American College of ...
(Date:3/20/2017)... CA (PRWEB) , ... March ... ... are substances that interfere with the ability of endogenous hormones to regulate ... inhibiting ligand binding activity (antagonists), EDCs produce adverse reproductive, neurological, proliferative, and ...
Breaking Biology Technology:
(Date:3/9/2017)... Australia , March 9, 2017 /PRNewswire/ ... at the prestigious World Lung Imaging Workshop at the ... Fouras , was invited to deliver the latest data ... This globally recognised event brings together leaders at the ... latest developments in lung imaging. "The ...
(Date:3/7/2017)... 2017   HireVue , the leading provider of ... the best talent, faster, today announced the additions of ... and Diana Kucer as Chief Marketing Officer ... team poised to drive continued growth in the company,s ... of record bookings in 2017. "Companies worldwide ...
(Date:3/2/2017)... -- Summary This report provides all the ... its partnering interests and activities since 2010. Download ... Partnering Deals and Alliance since 2010 report provides an ... the world,s leading life sciences companies. On ... inclusion of the most up to date deal and ...
Breaking Biology News(10 mins):